Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Mental Health Strategy 2024-2030

Executive Summary
 
We can all play a role in promoting and safeguarding mental health for all population groups and in supporting individuals going through difficult times. This strategy serves as a seven-year roadmap aimed at guiding the Ministry of Public Health and all relevant stakeholders while mobilizing efforts to improve mental health in Lebanon. In Lebanon, in particular, improving mental health also requires addressing the social, economic, and political factors that negatively impact mental well-being and hinder the recovery process.
 
The strategy was developed using a comprehensive approach to address key issues. First, an assessment of the mental health situation in the country was conducted, including the burden of diseases, needs, and an evaluation of the existing system’s ability to meet these needs. Previous efforts were also reviewed to identify areas that need to be maintained and those requiring improvement. Furthermore, consultations were held with experts and local stakeholders, including individuals with lived experiences, to help set strategic priorities. The strategy was also guided by international frameworks, including World Health Organization (WHO) guidelines and other evidence-based recommendations. Special care was taken to select approaches that are appropriate and adaptable to the local context. Finally, the strategy was published and made available to the public for feedback and revisions.
 
The strategy addresses all fundamental aspects of the mental health system to enhance overall mental well-being and prevent mental disorders, with a focus on the following key areas:
  • Raising awareness about mental health, reducing misconceptions, and implementing evidence-based interventions to prevent mental health issues. This includes emphasizing the importance of addressing political, social, and economic factors that influence mental health.
  • Empowering individuals by providing them with the resources, knowledge, and skills necessary to protect their mental well-being and ensuring access to available services when needed.
  • Ensuring that individuals with mental health disorders can access high-quality care whenever they need it, regardless of their place of residence.
  • Supporting healthcare providers and all professionals in the field by building their capacity based on evidence-based practices and helping them safeguard their own mental health.
  • Preventing and reducing harmful practices that violate human rights and quality standards in the provision of mental health services.
  • Enhancing data availability and conducting valuable research to guide and support efforts to improve mental health across the country.
  • Establishing legal frameworks, policies, and appropriate funding mechanisms to strengthen the mental health system.
  • Integrating the views, perspectives, and preferences of individuals with lived experiences in the design, development, and implementation of services, policies, and practices.
Specific actions have been planned for each of these key areas to ensure the necessary improvements in the country.
 

 
National Mental Health Strategy 2024-2030 (Please click on this link to download the document)
 
Theory of Change Map (Please click on this link to download the document)

Executive Summary (English, French, Arabic) 
 
    ...
    6
    ...
ATC Name B/G Ingredients Dosage Form Price
M01AE03 ARDBEG 80MG ADULTS G Ketoprofen Lysine salt - 80mg 80mg Powder for solution 634,294 L.L
M01AE02 ANODYNE 500 G Naproxen - 500mg 500mg Suppository 342,680 L.L
M01AE01 ADVIL LIQUI-GELS EXTRA STRENGTH B Ibuprofen - 400mg 400mg Capsule 575,165 L.L
M01AE01 ALGIFAST PEDIATRIC B Ibuprofen Lysine - 20mg/ml 20mg/ml Suspension 393,746 L.L
M01AE01 ALGIFAST 400 B Ibuprofen Lysine - 400mg 400mg Powder for suspension 473,033 L.L
M01AE01 ADVIL LIQUI-GELS B Ibuprofen - 200mg 200mg Capsule 464,970 L.L
M01AE01 ADVIL B Ibuprofen - 200mg 200mg Tablet 321,178 L.L
M01AB16 ARACENAC G Aceclofenac - 100mg 100mg Tablet, film coated 330,585 L.L
M01AB16 ACECLOFAR G Aceclofenac - 100mg 100mg Tablet 131,697 L.L
M01AB16 AIRTAL 100MG 20 B Aceclofenac - 100mg 100mg Tablet, film coated 471,689 L.L
M01AB15 ALGIKEY G Ketorolac trometamine - 30mg/ml 30mg/ml Injectable solution 873,498 L.L
M01AB05 ALMIRAL G Diclofenac sodium - 75mg/3ml 75mg/3ml Injectable solution 415,247 L.L
L04AD02 ADVAGRAF B Tacrolimus monohydrate - 0.5mg 0.5mg Capsule, prolonged release 13,297,758 L.L
L04AD02 ADVAGRAF B Tacrolimus monohydrate - 5mg 5mg Capsule, prolonged release 85,485,667 L.L
L04AD02 ADVAGRAF B Tacrolimus monohydrate - 1mg 1mg Capsule, prolonged release 25,729,044 L.L
L04AD02 ADVAGRAF B Tacrolimus monohydrate - 3mg 3mg Capsule, prolonged release 68,645,618 L.L
L04AC07 ACTEMRA BioTech Tocilizumab - 400mg/20ml 400mg/20ml Injectable concentrated solution 47,925,322 L.L
L04AC07 ACTEMRA BioTech Tocilizumab - 200mg/10ml 200mg/10ml Injectable concentrated solution 25,485,937 L.L
L04AC07 ACTEMRA BioTech Tocilizumab - 162mg/0.9ml 162mg/0.9ml Injectable solution 79,959,812 L.L
L04AC07 ACTEMRA BioTech Tocilizumab - 80mg/4ml 80mg/4ml Injectable concentrated solution 11,127,864 L.L
L04AB04 ADALIREL BioTech Adalimumab - 40mg 40mg Injectable solution 7,805,376 L.L
L04AB04 ABRILADA BioTech Adalimumab - 40mg 40mg Injectable solution 40,259,574 L.L
L04AB04 ABRILADA BioTech Adalimumab - 40mg 40mg Injectable solution 40,259,574 L.L
L04AB01 ALTEBREL BioTech Etanercept - 25mg/0.5ml 25mg/0.5ml Injectable solution 27,383,989 L.L
L04AB01 ALTEBREL BioTech Etanercept - 50mg/1ml 50mg/1ml Injectable solution 14,833,767 L.L
L04AA32 APRIVA G Apremilast - 30mg 30mg Tablet, film coated 41,455,526 L.L
L04AA32 APRIVA STARTER PACK G Apremilast - 10mg, Apremilast - 20mg, Apremilast - 30mg Tablet, film coated 22,154,866 L.L
L04AA31 AUBAGIO B Teriflunomide - 14mg 14mg Tablet, film coated 38,773,533 L.L
L04AA31 AUBAGIO B Teriflunomide - 14mg 14mg Tablet, film coated 38,773,533 L.L
L04AA13 AROTAN G Leflunomide - 20mg 20mg Tablet, film coated 2,014,420 L.L
    ...
    6
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025